Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme
- 2 March 2012
- journal article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 108 (1), 173-177
- https://doi.org/10.1007/s11060-012-0826-3
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma PatientsJournal of Clinical Oncology, 2008
- Canadian Recommendations for the Treatment of Glioblastoma MultiformeCurrent Oncology, 2007
- Safety and feasibility of long-term temozolomide treatment in patients with high-grade gliomaNeurology, 2007
- Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial GliomasJournal of Neuropathology and Experimental Neurology, 2005
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaThe New England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancerEuropean Journal of Cancer, 1999
- Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trialsCancer Treatment Reviews, 1997
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990